ReviewAlimentary pharmacology & therapeutics2014
Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
Review in Alimentary pharmacology & therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 68 citations in OpenAlex.
- Evaluation of the efficacy of polyethylene glycol in combination with different doses of linaclotide in a fractionated bowel preparation for colonoscopy: a prospective randomized controlled study.International journal of colorectal disease · 2024Trial
- Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia.Journal of neurogastroenterology and motility · 2026Article
- Patient-Centered Approach in IBS-C Management.Gastroenterology & hepatology · 2025Article
- Raising Expectations in IBS-C Management.Gastroenterology & hepatology · 2025Article
- A pharmacovigilance study of the association between linaclotide/plecanatide and muscle spasms based on food and drug administration adverse event reporting system.Frontiers in pharmacology · 2025Article
- A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.Gastroenterology & hepatology · 2024Article
- Discovery and Characterization of MaK: A Novel Knottin Antimicrobial Peptide fromInternational journal of molecular sciences · 2023Article
- Microbiota-derived butyrate dampens linaclotide stimulation of the guanylate cyclase C pathway in patient-derived colonoids.Neurogastroenterology and motility · 2023Article
- Imaging Classification of Constipation.Journal of the anus, rectum and colon · 2023Article
- Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Article
- DAKS1, a Kunitz Scaffold Peptide from the Venom Gland ofPharmaceuticals (Basel, Switzerland) · 2021Article
- Action Mode of Gut Motility, Fluid and Electrolyte Transport in Chronic Constipation.Frontiers in pharmacology · 2021Review
- Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation.Gastroenterology research and practice · 2020Article
- Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.BMC gastroenterology · 2019Observational
- Update on Pharmacotherapy for Irritable Bowel Syndrome.Current gastroenterology reports · 2019Review
- Observational
- Review
- Assigning biological function using hidden signatures in cystine-stabilized peptide sequences.Scientific reports · 2018Article
- Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivityWorld journal of gastroenterology · 2018Article
- In vitro-engineered non-antibody protein therapeutics.Protein & cell · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome with constipation (IBS-C) represents a significant burden to patients and healthcare systems due to its prevalence and lack of successful symptomatic resolution with established treatment options. Linaclotide 290 μg has recently been approved by the European Medicines Agency (EMA) for moderate-to-severe IBS-C and by the US Food and Drug Administration for IBS-C (290 μg dose) and for chronic constipation (145 μg dose).
aimTo summarise data leading to the approval of linaclotide for IBS-C, with focus on EMA-pre-specified outcome measures.
methodsLiterature search of a peer-review database (PubMed) and review of congress abstracts on linaclotide preclinical and clinical trial data in IBS-C.
resultsPreclinical studies suggest that the guanylate cyclase C agonist (GCCA) linaclotide acts through elevation of cyclic guanosine monophosphate (cGMP) levels, leading to accelerated gastrointestinal (GI) transit through increased fluid secretion and reduced visceral hypersensitivity. Clinical trial data demonstrate that linaclotide improves abdominal symptoms (pain, bloating) and bowel symptoms (constipation) compared with placebo in patients with IBS-C. The most frequent side effect, diarrhoea, results from the therapeutic action of linaclotide. Linaclotide acts locally in the GI tract with minimal systemic exposure, resulting in low oral bioavailability and thus a low risk of relevant systemic adverse effects.
conclusionLinaclotide, a first-in-class GCCA, is a promising new drug with a novel, dual mechanism of action that, unlike more well-established agents, can relieve the abdominal pain, bloating and constipation associated with IBS-C and has a low propensity for systemic side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.